Investigating ways to reactivate a gene to treat Rett Syndrome
Official title: Epigenetic and Neuronal Mechanisms of MECP2 Reactivation to rescue Rett Syndrome
Funded at Columbia University Health Sciences · NIH-10902891 · Data updated 2026-11-12
This study is looking at new ways to help people with Rett Syndrome by using special tools to turn on a gene that isn’t working properly, with the hope of easing their symptoms and improving their lives.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 16, 2024 |
| Project end | September 15, 2028 |
| Funding year | 2024 |
| Award (this year) | $50,414 |
| NIH project number | 1F30HD115371-01 |
| Project ID | NIH-10902891 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are females diagnosed with Rett Syndrome who have mutations in the MeCP2 gene.
✕Less likely to help
Patients with Rett Syndrome who do not have mutations in the MeCP2 gene or those with other unrelated neurodevelopmental disorders may not benefit from this research.
What this research studies
This research focuses on Rett Syndrome, a severe neurodevelopmental disorder caused by mutations in the MeCP2 gene. The study aims to explore innovative methods to reactivate the silenced, functional allele of this gene using CRISPR-based epigenome editing tools. By targeting specific areas of the genome, the researchers hope to improve the expression of the MeCP2 gene without the adverse effects associated with global reactivation. The ultimate goal is to understand the mechanisms behind this reactivation and its potential to alleviate symptoms in affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that significantly improve the quality of life for patients with Rett Syndrome.
How similar studies have gone: While there have been successful applications of CRISPR technology in other genetic disorders, the specific approach of targeted MeCP2 reactivation in Rett Syndrome is still novel and untested.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Pan, Richard Li Cheng — Columbia University Health Sciences
- Study coordinator: Pan, Richard Li Cheng
Related research
Other NIH-funded projects on the same topics.
-
Neuronal Cholesterol Enzyme CYP46A1 and Rett Syndrome biology
A study in Rett syndrome explores whether tweaking a brain cholesterol enzyme called CYP46A1 could help with the disease by affecting brain pathways involved in Rett.
-
Neurophysiological biomarkers to speed Rett syndrome therapies
A study to find measurable brain signals that show whether treatments are helping children with Rett syndrome.
-
MeCP2 reactivation on the inactive X to treat Rett syndrome
This project explores turning on the silent MECP2 gene on the inactive X chromosome to help people with Rett syndrome feel better.
-
Glial signaling and breathing in Rett syndrome
Aims to understand how brain support cells (glia) in Rett syndrome affect breathing and whether IGF-1 related signals can improve it.
-
Studying how deep brain stimulation helps Rett syndrome in mice
Researchers are testing how deep brain stimulation affects brain cells and memory in a mouse model of Rett syndrome to uncover mechanisms that could guide future therapies.
-
Molecular Pathways Behind Rett Syndrome in Humans
A patient-focused look at how changes in the MECP2 gene affect brain function and development in Rett syndrome.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.